|
Defining the Chemical Perturbome of Neural Development and Activity |
1DP2NS132107-01 |
|
NINDS |
2022 |
|
Chemical Control of Misfolded Protein Fate |
1DP2NS132610-01 |
|
NINDS |
2022 |
|
Parkinsons disease therapies targeting GUCY2C |
1F30NS125921-01A1 |
|
NINDS |
2022 |
|
Pathogenic mechanism of intrathecally synthesized immunoglobulins in a mouse model of progressive multiple sclerosis |
1F31NS118955-01A1 |
|
NINDS |
2022 |
|
Neural Mechanisms Supporting Implicit and Explicit Sensorimotor Learning |
1F31NS120448-01A1 |
|
NINDS |
2022 |
|
Engineered extracellular vesicles as a targeted drug delivery system for multiple sclerosis |
1F31NS120590-01A1 |
|
NINDS |
2022 |
|
Roles for astrocytic RIPK3 signaling in Parkinsons disease pathogenesis |
1F31NS124242-01A1 |
|
NINDS |
2022 |
|
Cellular Mechanisms of Insulin-like Growth Factor-1 Neuroprotection with Ischemic Stroke |
1F31NS124302-01A1 |
|
NINDS |
2022 |
|
A Novel Genome-Wide Screen to Identify and Characterize Regulators of ALS Disease Modifier Gene Ataxin-2 |
1F31NS125681-01 |
|
NINDS |
2022 |
|
The sex-specific role of alpha-synuclein |
1F31NS125963-01 |
|
NINDS |
2022 |